1 / 1
Zilebesiran API is an investigational small interfering RNA (siRNA) developed for the treatment of hypertension. It targets the AGT gene, which encodes angiotensinogen—a key component of the renin-angiotensin-aldosterone system (RAAS). In research, Zilebesiran is used to study gene silencing approaches for long-term blood pressure control, RNAi delivery technologies, and the broader role of the RAAS pathway in cardiovascular and renal diseases.
Zilebesiran functions by silencing AGT mRNA in the liver, resulting in reduced production of angiotensinogen. This leads to a downstream decrease in angiotensin II levels, helping to lower blood pressure in a sustained manner. As an API, Zilebesiran enables the development of long-acting, subcutaneous antihypertensive therapies with the potential for quarterly or biannual dosing, offering improved adherence and blood pressure management.
Zilebesiran API is an investigational small interfering RNA (siRNA) developed for the treatment of hypertension.
Zilebesiran targets the AGT gene in the liver, which encodes angiotensinogen—a key component of the renin-angiotensin-aldosterone system (RAAS).
It functions by silencing AGT mRNA, reducing angiotensinogen production and downstream angiotensin II levels to achieve sustained blood pressure reduction.
In research, it is utilized to study gene silencing approaches for long-term blood pressure control, RNAi delivery technologies, and the role of the RAAS pathway in cardiovascular and renal diseases.
It enables the development of long-acting, subcutaneous antihypertensive therapies with the potential for quarterly or biannual dosing, promoting better treatment adherence.
